Lim Y C, Hong H J, Baek S J, Park J H, Kim G E, Lee C G, Lew D H, Lee W J, Choi E C
Department of Otorhinolaryngology-Head and Neck Surgery, Konkuk University School of Medicine, Seoul, South Korea.
Int J Oral Maxillofac Surg. 2008 Dec;37(12):1099-105. doi: 10.1016/j.ijom.2008.07.002. Epub 2008 Aug 22.
The treatment of oropharyngeal squamous cell carcinoma (OSCC) remains controversial. This study reviews the authors' experience of treating OSCC, evaluates the oncologic outcome and assesses the factors affecting local/regional recurrence. A retrospective analysis of 110 consecutive OSCC patients treated primarily by surgery and/or postoperative radiotherapy was carried out. 82% of patients had advanced disease (stage III or IV). The 5-year overall survival and disease specific survival rates (DSSR) were 58% and 65%, respectively. The DSSR of the soft palate or posterior pharyngeal wall, tonsillar area, and base of tongue were 80%, 62%, and 51%, respectively (P<0.05). The 5-year DSSR according to the American Joint Committee on Cancer stages was 94% for early stage and 56% for advanced stage (P<0.05). The overall recurrence rate was 38% (42 patients). The most frequent site of recurrence was the neck (46%). Only 14% of patients with recurrences were treated successfully. Positive resection margins and the presence of pathologic lymph nodes influenced the recurrence at the primary lesion and in the neck, respectively, in a statistically significant manner. Surgery and postoperative radiotherapy provided a superior outcome in patients with advanced OSCC. A randomized study is required to assess the oncologic and functional superiority of surgery or chemoradiation.
口咽鳞状细胞癌(OSCC)的治疗仍存在争议。本研究回顾了作者治疗OSCC的经验,评估了肿瘤学结局,并分析了影响局部/区域复发的因素。对110例主要接受手术和/或术后放疗的连续性OSCC患者进行了回顾性分析。82%的患者患有晚期疾病(III期或IV期)。5年总生存率和疾病特异性生存率(DSSR)分别为58%和65%。软腭或咽后壁、扁桃体区和舌根的DSSR分别为80%、62%和51%(P<0.05)。根据美国癌症联合委员会分期,早期患者的5年DSSR为94%,晚期患者为56%(P<0.05)。总复发率为38%(42例患者)。最常见的复发部位是颈部(46%)。复发患者中只有14%得到了成功治疗。切缘阳性和病理淋巴结的存在分别对原发灶和颈部的复发有统计学意义的影响。手术和术后放疗为晚期OSCC患者提供了更好的结局。需要进行一项随机研究来评估手术或放化疗在肿瘤学和功能方面的优越性。